journal article·2016-03-09Open access

The Use of Minimal RNA Toeholds to Trigger the Activation of Multiple Functionalities

Kirill A. Afonin, Mathias Viard, Philip Tedbury, Eckart Bindewald, Lorena Parlea, Marshall Howington, Melissa Valdman, Alizah Johns-Boehme, Cara Brainerd, Eric O. Freed, Bruce A. Shapiro

Nano Letters· Volume 16· Issue 3

Abstract

Current work reports the use of single-stranded RNA toeholds of different lengths to promote the reassociation of various RNA-DNA hybrids, which results in activation of multiple split functionalities inside human cells. The process of reassociation is analyzed and followed with a novel computational multistrand secondary structure prediction algorithm and various experiments. All of our previously designed RNA/DNA nanoparticles employed single-stranded DNA toeholds to initiate reassociation. The use of RNA toeholds is advantageous because of the simpler design rules, the shorter toeholds, and the smaller size of the resulting nanoparticles (by up to 120 nucleotides per particle) compared to the same hybrid nanoparticles with single-stranded DNA toeholds. Moreover, the cotranscriptional assemblies result in higher yields for hybrid nanoparticles with ssRNA toeholds.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · RNA and protein synthesis mechanisms

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Gene Regulation and Chromosome Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States

Department of Chemistry, University of North Carolina at Charlotte, 9201 University City Boulevard, Charlotte, North Carolina 28223, United States

Basic Science Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702, United States

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States

Funding

National Cancer Institute · National Heart, Lung, and Blood Institute · National Institute of Allergy and Infectious Diseases

References (50)

Show source-provided references
1. 10.1101/gad.86230110.1101/gad.862301 ↗
2. 10.1093/emboj/20.23.687710.1093/emboj/20.23.6877 ↗
3. 10.1038/3588810.1038/35888 ↗
4. 10.1515/rnan-2015-000110.1515/rnan-2015-0001 ↗
5. 10.1007/978-1-61779-037-9_510.1007/978-1-61779-037-9_5 ↗
6. Bramsen J. B. · Front Genet. · 2012 · 3 · 15410.3389/fgene.2012.00154 ↗
7. 10.1038/nprot.2011.41810.1038/nprot.2011.418 ↗
8. 10.2478/rnan-2013-000110.2478/rnan-2013-0001 ↗
9. 10.1021/nn504508s10.1021/nn504508s ↗
10. 10.1021/nl502385k10.1021/nl502385k ↗
11. 10.1038/nnano.2010.23110.1038/nnano.2010.231 ↗
12. 10.1021/nl051264s10.1021/nl051264s ↗
13. 10.1021/nn500625410.1021/nn5006254 ↗
14. 10.1021/nn200989r10.1021/nn200989r ↗
15. 10.1021/bi401702210.1021/bi4017022 ↗
16. Guo P. · Nucleic Acid Ther. · 2012 · 22 · 22610.1089/nat.2012.0350 ↗
17. 10.1093/nar/gku51610.1093/nar/gku516 ↗
18. 10.1093/nar/gkt88510.1093/nar/gkt885 ↗
19. 10.1038/nnano.2011.10510.1038/nnano.2011.105 ↗
20. 10.1039/c1cc11780g10.1039/c1cc11780g ↗
21. 10.1021/nn502253c10.1021/nn502253c ↗
22. 10.1021/nn506962210.1021/nn5069622 ↗
23. 10.1007/s11095-013-1226-x10.1007/s11095-013-1226-x ↗
24. 10.1021/acsnano.5b0006710.1021/acsnano.5b00067 ↗
25. 10.1261/rna.037002.11210.1261/rna.037002.112 ↗
26. 10.1021/ar400329z10.1021/ar400329z ↗
27. 10.1038/nnano.2013.4410.1038/nnano.2013.44 ↗
28. 10.1093/nar/gkt100110.1093/nar/gkt1001 ↗
29. 10.1016/bs.mie.2014.10.05810.1016/bs.mie.2014.10.058 ↗
30. 10.1093/nar/gkt100110.1093/nar/gkt1001 ↗
31. 10.1021/sb500072510.1021/sb5000725 ↗
32. 10.1038/nnano.2010.16010.1038/nnano.2010.160 ↗
33. 10.1016/j.ymeth.2013.10.01310.1016/j.ymeth.2013.10.013 ↗
34. 10.1021/nl104271s10.1021/nl104271s ↗
35. El Tannir Z. · RNA Disease · 2015 · 2 · e724
36. 10.1093/nar/gki73210.1093/nar/gki732 ↗
37. 10.1016/j.antiviral.2011.04.00210.1016/j.antiviral.2011.04.002 ↗
38. 10.1038/mt.2009.17610.1038/mt.2009.176 ↗
39. 10.1038/mt.2011.29910.1038/mt.2011.299 ↗
40. 10.1038/sj.mt.630038210.1038/sj.mt.6300382 ↗
41. 10.1021/nl302302e10.1021/nl302302e ↗
42. 10.1093/nar/gkr92610.1093/nar/gkr926 ↗
43. 10.1126/science.125392010.1126/science.1253920 ↗
44. 10.1016/j.bpj.2015.01.02310.1016/j.bpj.2015.01.023 ↗
45. 10.1006/jmbi.2000.395110.1006/jmbi.2000.3951 ↗
46. 10.1016/j.jconrel.2015.06.04110.1016/j.jconrel.2015.06.041 ↗
47. 10.2217/nnm.15.10510.2217/nnm.15.105 ↗
48. 10.1038/mtna.2013.510.1038/mtna.2013.5 ↗
49. Adachi A. · J. Virol. · 1986 · 59 · 28410.1128/jvi.59.2.284-291.1986 ↗
50. Willey R. L. · J. Virol. · 1988 · 62 · 13910.1128/jvi.62.1.139-147.1988 ↗